Good News and Bad News-4CMenB Vaccine for Group B Neisseria meningitidis
Authors:
- 23 January 2020
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 382 (4) , 376-378
Abstract
Neisseria meningitidis remains a major cause of meningitis, sepsis, and other serious infections globally. Almost all meningococcal infections are caused by one of six capsular groups (A, B, C, W, X, and Y) that are distinguished by different biochemical compositions of the polysaccharide capsules. Over the past two decades, the use of meningococcal capsular polysaccharide–protein conjugate vaccines has led to major successes in the prevention of invasive meningococcal disease. For example, the introduction of monovalent meningococcal capsular group A conjugate vaccine in the “African meningitis belt” (from Senegal to Ethiopia) and meningococcal group C conjugate vaccine in the United Kingdom . . .Keywords
This publication has 12 references indexed in Scilit:
- Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in EnglandNew England Journal of Medicine, 2020
- Meningococcal B Vaccine and Meningococcal Carriage in Adolescents in AustraliaNew England Journal of Medicine, 2020
- Meningococcal Carriage Following a Vaccination Campaign With MenB-4C and MenB-FHbp in Response to a University Serogroup B Meningococcal Disease Outbreak—Oregon, 2015–2016The Journal of Infectious Diseases, 2017
- Impact of MenAfriVac in nine countries of the African meningitis belt, 2010–15: an analysis of surveillance dataThe Lancet Infectious Diseases, 2017
- Boosters for meningococcal B vaccines?The Lancet Infectious Diseases, 2017
- Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort studyThe Lancet, 2016
- Vaccines for prevention of group B meningococcal disease: Not your father's vaccinesVaccine, 2015
- Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015MMWR. Morbidity and Mortality Weekly Report, 2015
- Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trialThe Lancet, 2014
- Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd ImmunityClinical and Vaccine Immunology, 2010